AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19834313 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.d, n=26)
Number of subjects: 107
Study 19834313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) (35 g ethinyl estradiol/2 mg cyproterone acetate, n=30)
Number of subjects: 107
Study 19834313 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without PCOS, n=27)
Number of subjects: 107
Study 18030228 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 8 weeks
Number of subjects: 148
Study 18030228 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 8 weeks
Number of subjects: 148
Study 18030228 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg and 40 mg once daily for 8 weeks
Number of subjects: 148
Study 15803017 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 microg/kg)
Number of subjects: 22
Study 15803017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.1 mg/kg)
Number of subjects: 22
Study 11871213 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/high simple carbohydrate diet
Number of subjects: 398
Study 11871213 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/high complex carbohydrate diet
Number of subjects: 398
Study 11871213 — intervention group
Group type: COMPARATOR
Intervention: Control diet group with normal macronutrient intake
Number of subjects: 398
Study 11871213 — intervention group
Group type: COMPARATOR
Intervention: Seasonal control group
Number of subjects: 398
Study 10195516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mL/kg 1% lidocaine i.v.
Number of subjects: 100
Study 10195516 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mL/kg isotonic sodium chloride solution (placebo control)
Number of subjects: 100
Study 7760868 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (5 micrograms per kilogram of body weight per day intravenously over a period of six hours)
Number of subjects: 388
Study 7760868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 1994608 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous deflation prior to emergency tube decompression followed electively by colopexy with banding (n = 20)
Number of subjects: 41
Study 1994608 — intervention group
Group type: COMPARATOR
Intervention: Emergency tube decompression followed electively by sigmoid colectomy (n = 21)
Number of subjects: 41
Study 1994608 — intervention group
Group type: EXPERIMENTAL
Intervention: Colopexy by banding
Number of subjects: 41
Study 1994608 — intervention group
Group type: COMPARATOR
Intervention: Both elective procedures (colopexy and sigmoid colectomy)
Number of subjects: 41
Study 6140939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride (400 mg)
Number of subjects: 9
Study 6140939 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 9
Study 6140939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30702971 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib with neoadjuvant chemotherapy (NAC)
Number of subjects: 156
Study 29339565 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding the Baby (MTB) home visiting program
Number of subjects: 158
Study 29339565 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study 24335026 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (250 mg 3 times a day for 7 days)
Number of subjects: 152
Study 22972538 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release doxylamine-pyridoxine (Diclectin)
Number of subjects: 258
Study 22972538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 19605828 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting
Number of subjects: 3000
Study 19605828 — intervention group
Group type: COMPARATOR
Intervention: Open harvesting
Number of subjects: 3000
Study 17395756 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity exercise
Number of subjects: 240
Study 17395756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount/vigorous-intensity exercise
Number of subjects: 240
Study 17395756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount/moderate-intensity exercise
Number of subjects: 240
Study 17395756 — intervention group
Group type: COMPARATOR
Intervention: Control (inactivity)
Number of subjects: 240
Study 15460211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine (IbuLys) 400 mg (two tablets of Dolormin as a single dose)
Number of subjects: 0
Study 15460211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Ibu) 400 mg (two tablets as a single dose)
Number of subjects: 0
Study 15460211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 0
Study 11433224 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 (50 or 100 mg twice daily)
Number of subjects: 11
Study 9460566 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Cell Dyn 4000 (CD4000)
Number of subjects: 695
Study 9460566 — intervention group
Group type: COMPARATOR
Intervention: FACScan
Number of subjects: 695
Study 9460566 — intervention group
Group type: COMPARATOR
Intervention: Sysmex R1000
Number of subjects: 695
Study 9460566 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4000 IRF
Number of subjects: 695
Study 8179848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (1, 5, or 10 mg)
Number of subjects: 240
Study 8179848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 or 25 mg)
Number of subjects: 240
Study 8179848 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebivolol and hydrochlorothiazide
Number of subjects: 240
Study 8179848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg combined with hydrochlorothiazide 25 mg
Number of subjects: 240
Study 8179848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 3069520 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg choline theophyllinate administered orally every 12 h for 7 days
Number of subjects: 18
Study 3069520 — intervention group
Group type: COMPARATOR
Intervention: 300 mg anhydrous theophylline administered orally every 12 h for 7 days
Number of subjects: 18
Study 3069520 — intervention group
Group type: COMPARATOR
Intervention: 300 mg anhydrous theophylline
Number of subjects: 18
Study 3069520 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg choline theophyllinate
Number of subjects: 18
Study 29648853 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIP plus IMP
Number of subjects: 160
Study 29648853 — intervention group
Group type: COMPARATOR
Intervention: SBIP
Number of subjects: 160
Study 25824436 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal-directed hypnotherapy (EHYP) - 7 weekly sessions
Number of subjects: 0
Study 24964299 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 40
Study 24964299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (Group K)
Number of subjects: 40
Study 24964299 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (both groups)
Number of subjects: 40
Study 22746968 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous training with feedback from simulated patients and peers
Number of subjects: 0
Study 22746968 — intervention group
Group type: COMPARATOR
Intervention: Traditional training with supervising physician
Number of subjects: 0
Study 22746968 — intervention group
Group type: COMPARATOR
Intervention: Online training based on video fragments
Number of subjects: 0
Study 19889113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 125 microg
Number of subjects: 600
Study 19889113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 150 microg
Number of subjects: 600
Study 19889113 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (0.5 ml) 1 min before administration of fentanyl 150 microg
Number of subjects: 600
Study 19034284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy for colorectal cancer
Number of subjects: 2481
Study 16150800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at 15 mmHg
Number of subjects: 8
Study 16150800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at 35 mmHg
Number of subjects: 8
Study 16150800 — intervention group
Group type: COMPARATOR
Intervention: Baseline (0 mmHg LBNP)
Number of subjects: 8
Study 13129460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut flour (200-250 g/kg) in macaroons
Number of subjects: 20
Study 13129460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut flour (200-250 g/kg) in carrot cake
Number of subjects: 20
Study 13129460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut flour (150 g/kg) in test foods
Number of subjects: 20
Study 13129460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut flour (50 g/kg) in pan de sal
Number of subjects: 20
Study 13129460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut flour (100 g/kg) in multigrain loaf
Number of subjects: 20
Study 13129460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut flour (50 g/kg) in granola bar
Number of subjects: 20
Study 13129460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut flour (100 g/kg) in cinnamon bread
Number of subjects: 20
Study 10814909 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDCAB
Number of subjects: 150
Study 10814909 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 150
Study 8690829 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 20
Study 8690829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (MIR)
Number of subjects: 20
Study 8690829 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched controls)
Number of subjects: 20
Study 1626680 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 5 micrograms.kg‐1
Number of subjects: 20
Study 1626680 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium 0 (Control)
Number of subjects: 20
Study 6100497 — intervention group
Group type: COMPARATOR
Intervention: Low dose methotrexate regime (three cycles of etoposide, adriamycin and methotrexate at conventional dosage)
Number of subjects: 83
Study 6100497 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methotrexate regime (three cycles of etoposide and adriamycin with five courses of high dose methotrexate and folinic acid rescue)
Number of subjects: 83
Study 6100497 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete responders
Number of subjects: 83
Study 6100497 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial responders
Number of subjects: 83
Study 6100497 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative four drug regime (procarbazine, vincristine, cyclophosphamide and CCNU)
Number of subjects: 83
Study 31161374 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided 125I brachytherapy (group A)
Number of subjects: 95
Study 31161374 — intervention group
Group type: COMPARATOR
Intervention: Supportive and symptomatic treatments (group B)
Number of subjects: 95
Study 29590046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibers promoting SCFA-producing strains
Number of subjects: 0
Study 27122359 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet program-DirectLife (Philips) aimed at increasing physical activity with monitoring and feedback by accelerometry and digital coaching
Number of subjects: 235
Study 27122359 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet program-DirectLife (Philips) for participants who reached physical activity target
Number of subjects: 235
Study 27122359 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in minutes spent in moderate-to-vigorous physical activity (MVPA)
Number of subjects: 235
Study 27122359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 235
Study 24495481 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 524
Study 24495481 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 524
Study 22274684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (15 mg/d if <30 kg; 30 mg/d if ≥30 kg)
Number of subjects: 306
Study 22274684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 22274684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 306
Study 20861834 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrichment-window strategy applied before standard statistical analysis
Number of subjects: 1837
Study 20861834 — intervention group
Group type: COMPARATOR
Intervention: Traditional multicenter randomized clinical trials (RCTs)
Number of subjects: 1837
Study 17923420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses who reported at least one sharps injury; 49.6% recalled at least one sharps injury (95% CI 47.1%-52.1%).
Number of subjects: 2118
Study 17923420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses who reported sustaining between 1 and 4 injuries; 75.6% recalled this (95% CI 71.1%-79.6%).
Number of subjects: 2118
Study 17923420 — intervention group
Group type: COMPARATOR
Intervention: Registered nurses and midwives compared to nurse managers; OR 1.6 (95% CI 1.1-2.3) for registered nurses, OR 2.4 (95% CI 1.4-3.9) for midwives.
Number of subjects: 2118
Study 17923420 — intervention group
Group type: COMPARATOR
Intervention: Nurses with a previous contaminated NSI; OR 0.3 (95% CI 0.2-0.4).
Number of subjects: 2118
Study 16272867 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Wilson disease
Number of subjects: 47
Study 16272867 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 47
Study 16272867 — intervention group
Group type: COMPARATOR
Intervention: Patients with Parkinson disease
Number of subjects: 47
Study 16272867 — intervention group
Group type: COMPARATOR
Intervention: Patients with multiple sclerosis
Number of subjects: 47
Study 12228773 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol administered twice daily for 8 months
Number of subjects: 150
Study 12228773 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 150
Study 10212732 — intervention group
Group type: EXPERIMENTAL
Intervention: PACST test consisting of 60 Yes-No questions
Number of subjects: 0
Study 10212732 — intervention group
Group type: COMPARATOR
Intervention: Normal performance group
Number of subjects: 0
Study 10212732 — intervention group
Group type: COMPARATOR
Intervention: Impaired performance group
Number of subjects: 0
Study 10212732 — intervention group
Group type: COMPARATOR
Intervention: Chance performance group
Number of subjects: 0
Study 8560136 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphic assessment method for periodic leg movements (PLM)
Number of subjects: 30
Study 2151874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (125 micrograms/kg)
Number of subjects: 24
Study 2151874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (25 micrograms/kg)
Number of subjects: 24
Study 2151874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fentanyl and sufentanil
Number of subjects: 24
Study 322671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam (2 mg orally) administered for 7 consecutive evenings
Number of subjects: 33
Study 322671 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 days
Number of subjects: 33
Study 29352401 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice condition (offered choice of intervention from PMTO formats or services-as-usual)
Number of subjects: 129
Study 29352401 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training-Oregon Model (PMTO)
Number of subjects: 129
Study 29352401 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual (SAU) within the no-choice condition
Number of subjects: 129
Study 29352401 — intervention group
Group type: COMPARATOR
Intervention: No-choice condition (randomized to one of the four intervention conditions)
Number of subjects: 129
Study 28917235 — intervention group
Group type: EXPERIMENTAL
Intervention: new amino acid-based formula (nAAF)
Number of subjects: 36
Study 28917235 — intervention group
Group type: COMPARATOR
Intervention: commercial amino acid-based formula (cAAF)
Number of subjects: 36
Study 25520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of label options prior to smelling (normosmic subjects)
Number of subjects: 200
Study 25520045 — intervention group
Group type: COMPARATOR
Intervention: Presentation of label options after smelling (normosmic subjects)
Number of subjects: 200
Study 25520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal descriptors only (both groups)
Number of subjects: 200
Study 25520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal descriptors and pictures (both groups)
Number of subjects: 200
Study 22735897 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Anxiety and Social Skills Intervention (MASSI) program
Number of subjects: 30
Study 21688560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 177
Study 21688560 — intervention group
Group type: COMPARATOR
Intervention: Aromatase Inhibitors (AIN's)
Number of subjects: 177
Study 19214594 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga of Awareness program (gentle yoga poses, meditation, and breathing exercises)
Number of subjects: 37
Study 19214594 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga of Awareness program
Number of subjects: 37
Study 19214594 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 37
Study 16766370 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial decompression
Number of subjects: 90
Study 16766370 — intervention group
Group type: COMPARATOR
Intervention: Graded physiotherapy and exercises
Number of subjects: 90
Study 16766370 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported outcomes after 4-8 years
Number of subjects: 90
Study 16766370 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in indices after 4 years
Number of subjects: 90
Study 12720065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (n = 9)
Number of subjects: 20
Study 12720065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 20
Study 10698481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 22
Study 9119980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 1000 mg daily for 3 days
Number of subjects: 22
Study 9119980 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone 48 mg daily for one week, 24 mg daily for one week, and 12 mg daily for one week
Number of subjects: 22
Study 9119980 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone regimen
Number of subjects: 22
Study 8222034 — intervention group
Group type: COMPARATOR
Intervention: Sitting position with 2.0 ml hyperbaric bupivacaine 0.5%
Number of subjects: 50
Study 8222034 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position with 2.0 ml hyperbaric bupivacaine 0.5%
Number of subjects: 50
Study 3531044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (DDS) approximately 2 mg per kilogram body weight per day for 21 days
Number of subjects: 50
Study 3531044 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the drug)
Number of subjects: 50
Study 31132088 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference-adapted GLB program
Number of subjects: 43
Study 31132088 — intervention group
Group type: COMPARATOR
Intervention: In-person GLB program
Number of subjects: 43
Study 30095769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 130
Study 30095769 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 130
Study 27779460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Number of subjects: 0
Study 27779460 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine + Enalapril
Number of subjects: 0
Study 25490803 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-leveling pallet carousel
Number of subjects: 13
Study 25490803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable cart
Number of subjects: 13
Study 25490803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of self-leveling carousel and adjustable cart
Number of subjects: 13
Study 25490803 — intervention group
Group type: COMPARATOR
Intervention: Traditional palletizing conditions
Number of subjects: 13
Study 22468424 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-improving interpersonal affect regulation
Number of subjects: 0
Study 22468424 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-worsening interpersonal affect regulation
Number of subjects: 0
Study 20224931 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3) for 4 weeks
Number of subjects: 11
Study 20224931 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout period after probiotic
Number of subjects: 11
Study 20224931 — intervention group
Group type: COMPARATOR
Intervention: Baseline (pre-probiotic)
Number of subjects: 11
Study 20224931 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3) for 4 weeks in high oxalate absorbers
Number of subjects: 11
Study 18565465 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention promoting awareness of satiety cues and discouraging bottles containing more than 6 ounces before 4 months of age.
Number of subjects: 104
Study 18565465 — intervention group
Group type: COMPARATOR
Intervention: Control group received education regarding introduction and feeding of solid food after 4 months of age.
Number of subjects: 104
Study 15973772 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 51
Study 15973772 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 51
Study 12047603 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (TL)
Number of subjects: 10
Study 12047603 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam (TH)
Number of subjects: 10